University of California, San Diego

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Diego sits in the top decile of US sponsors by registered trial count (#43 of 15,742 sponsors by registered trial count).

775 total trials 143 currently recruiting 499 completed early-phase tilt top decile by trial count

University of California, San Diego: 775 sponsored US clinical trials, 143 recruiting.

University of California, San Diego sponsors 775 registered US clinical trials on ClinicalTrials.gov, 143 of them currently recruiting, and 499 completed. 104 of these trials are in Phase 3-4 (later-stage) and 170 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anorexia Nervosa, with 10 trials.

Top-decile sponsor footprint

University of California, San Diego ranks in the top decile of sponsors by registered trial count (#43 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

499 of 553 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

775 total, page 2 of 16

RECRUITING Phase 2

Elranatamab in Relapsed/Refractory Multiple Myeloma

NCT06711705

RECRUITING Phase 1

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

NCT06639724

RECRUITING NA

Intervening on Women's Health for Rural Young Cancer Survivors

NCT06664034

RECRUITING Early Phase 1

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

NCT06582888

RECRUITING Phase 3

BladdEr Full OR Empty for Pelvic Radiation Therapy

NCT06651697

RECRUITING NA

Meditative Neurofeedback for Depression

NCT06675240

RECRUITING Phase 3

Total RadIoTherapy of Oligometastatic caNcerS

NCT06587490

RECRUITING Phase 4

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

NCT06665971

RECRUITING NA

Ketogenic Diet and Brain Response in Anorexia Nervosa

NCT06540703

RECRUITING Phase 2

Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)

NCT06273527

RECRUITING

Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

NCT06706856

RECRUITING NA

Women Focused Encounters for Resilience Independence Strength and Eudaimonia

NCT06216600

RECRUITING Phase 3

Coenzyme Q10 for Gulf War Illness: A Replication Study

NCT06515184

RECRUITING Phase 1

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

NCT05696366

RECRUITING

Leveraging Artificial Intelligence and Multi-Omics Data to Predict Opioid Addiction

NCT06540105

RECRUITING Phase 1

THC Effects on Glucose in Type 2 Diabetes

NCT05322213

RECRUITING Phase 2

Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

NCT06981234

RECRUITING NA

Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)

NCT06721975

RECRUITING Phase 1

Pilot Study of Preoperative Intestinal Training Using Antegrade Ileostomy Infusion

NCT06461559

RECRUITING

Avoidance-driven Decision Making and Learning in Anorexia Nervosa and Bulimia Nervosa

NCT06566612

RECRUITING NA

Developing and Testing a Self-Compassion Tool Kit to Improve the Care of Individuals With Type 2 Diabetes

NCT06398093

RECRUITING NA

Short-term And Longer-term Cognitive Impact Of Neurochecks

NCT06219889

RECRUITING Phase 1

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

NCT06205849

RECRUITING NA

Effects of Hypoxic Breathwork

NCT06317259

RECRUITING Phase 4

A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty

NCT07282782

RECRUITING Phase 1

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

NCT06482268

RECRUITING Phase 1

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

NCT06393101

RECRUITING Phase 2

Mindfulness Engaged Neurostimulation for Depression

NCT06399406

RECRUITING Phase 2

Pramipexole to Enhance Social Connections

NCT06269146

RECRUITING NA

Family, Responsibility, Education, Support, and Health for Food Responsiveness

NCT06207110

RECRUITING Phase 2

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

NCT05787639

RECRUITING Phase 4

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

NCT06385236

RECRUITING Phase 2

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05237505

RECRUITING

Focal Therapy for Localized Prostate Cancer

NCT06270043

RECRUITING NA

Multisite Implementation of COMPRENDO

NCT06055296

RECRUITING Early Phase 1

Time Restricted Eating in Sleep Apnea

NCT06047496

RECRUITING NA

Enhancing Team Effectiveness for a Collaborative School-based Intervention for ADHD

NCT06180681

RECRUITING

Multi-Omics for Maternal Health After Preeclampsia

NCT06340152

RECRUITING

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

NCT06579417

RECRUITING

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

NCT05705219

RECRUITING NA

Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)

NCT05882253

RECRUITING NA

Flow and Grow - The Ideal Time to Wean CPAP Off In Extremely Low Birth Weight Infants

NCT06123143

RECRUITING NA

ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services

NCT06128304

RECRUITING

Next Generation Chest X-Ray Tomosynthesis for Screening of Lung Cancer

NCT06577883

RECRUITING

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

NCT06311123

RECRUITING NA

Therapeutic Ketogenic Diet in Anorexia Nervosa

NCT06000774

RECRUITING NA

Effect of Anti-inflammatory Diet in Osteoarthritis

NCT06080347

RECRUITING NA

Combined Neuromodulation and Cognitive Training for Post-mTBI Depression

NCT05682677

RECRUITING Phase 2

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

NCT05514899

RECRUITING NA

Effect of Mediterranean Diet in Inflammatory Bowel Disease

NCT05973500

← Previous Page 2 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 90
Phase 3 22
Phase 4 82

What is open in the University of California, San Diego pipeline

143 recruiting of 775 indexed (18% open); 499 completed (64%).

Phase mix: 104 late (III/IV) vs 170 early (I/II) (early-phase heavy).

Top condition: Anorexia Nervosa (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Diego: open-pipeline peers nationwide

Peers matched on 775 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of California, San DiegoDana-Farber Cancer InstituteMedical University of South CarolinaUniversity of ChicagoUniversity of UtahNeurocrine BiosciencesThomas Jefferson UniversityAbramson Cancer Center at Penn MedicineUniversity of Maryland, Baltimore
University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 775 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, San Diego page

775 registered trials is a research-attention snapshot, not an endorsement of University of California, San Diego or any single study.

  • 143 of University of California, San Diego's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Anorexia Nervosa is the condition University of California, San Diego studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anorexia Nervosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of California, San Diego pipeline card: 775 registered trials from official public datasets.Report a data error.